221 related articles for article (PubMed ID: 33847621)
1. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study.
Zhu J; Liang X; Wu D; Chen S; Yang B; Mao W; Shen D
Medicine (Baltimore); 2021 Apr; 100(15):e25237. PubMed ID: 33847621
[TBL] [Abstract][Full Text] [Related]
2. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of neuroendocrine prostate cancer.
Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
[TBL] [Abstract][Full Text] [Related]
5. Current trend of worsening prognosis of prostate small cell carcinoma: A population-based study.
Wang J; Liu X; Wang Y; Ren G
Cancer Med; 2019 Nov; 8(15):6799-6806. PubMed ID: 31518071
[TBL] [Abstract][Full Text] [Related]
6. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
[TBL] [Abstract][Full Text] [Related]
7. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.
Zhang Q; Han Y; Zhang Y; Liu D; Ming J; Huang B; Qiu X
Front Oncol; 2020; 10():571308. PubMed ID: 33598420
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer.
Alanee S; Moore A; Nutt M; Holland B; Dynda D; El-Zawahry A; McVary KT
Anticancer Res; 2015 Jul; 35(7):4145-50. PubMed ID: 26124369
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
Cattrini C; Cerbone L; Rubagotti A; Zinoli L; Latocca MM; Messina C; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2019 Aug; 17(4):e724-e732. PubMed ID: 31160193
[TBL] [Abstract][Full Text] [Related]
10. The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma.
Xu B; Chu Y; Hu Q; Song Q
Technol Cancer Res Treat; 2021; 20():15330338211055340. PubMed ID: 34806493
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study.
Wu YP; Chen SH; Wang ST; Li XD; Cai H; Lin YZ; Xue XY; Wei Y; Zheng QS; Xu N
Oncotarget; 2017 Apr; 8(17):29048-29055. PubMed ID: 28423709
[TBL] [Abstract][Full Text] [Related]
12. Treatment Outcomes in Neuroendocrine Prostate Cancer.
Iwamoto H; Nakagawa R; Makino T; Kadomoto S; Yaegashi H; Nohara T; Shigehara K; Izumi K; Kadono Y; Mizokami A
Anticancer Res; 2022 Apr; 42(4):2167-2176. PubMed ID: 35347041
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics and survival outcomes in neuroendocrine carcinoma of the ovary.
Zhu Y; Meng F; Fang H; Zhang Z; Wang L; Zheng W
Int J Gynecol Cancer; 2020 Feb; 30(2):207-212. PubMed ID: 31796530
[TBL] [Abstract][Full Text] [Related]
14. Nomograms predict survival outcomes for distant metastatic pancreatic neuroendocrine tumor: A population based STROBE compliant study.
Li G; Tian ML; Bing YT; Wang HY; Yuan CH; Xiu DR
Medicine (Baltimore); 2020 Mar; 99(13):e19593. PubMed ID: 32221079
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.
Eule CJ; Hu J; Al-Saad S; Collier K; Boland P; Lewis AR; McKay RR; Narayan V; Bosse D; Mortazavi A; Rose TL; Costello BA; Bryce AH; Lam ET
Clin Genitourin Cancer; 2023 Aug; 21(4):483-490. PubMed ID: 37193610
[TBL] [Abstract][Full Text] [Related]
16. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
Shou J; Zhang Q; Wang S; Zhang D
Prostate; 2018 May; 78(7):491-497. PubMed ID: 29436722
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China.
Liu D; Kuai Y; Zhu R; Zhou C; Tao Y; Han W; Chen Q
Sci Rep; 2020 Jun; 10(1):9104. PubMed ID: 32499554
[TBL] [Abstract][Full Text] [Related]
18. The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.
Wang R; Zhu Y; Liu X; Liao X; He J; Niu L
BMC Cancer; 2019 Nov; 19(1):1091. PubMed ID: 31718602
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis.
Yang Q; Xu Z; Chen X; Zheng L; Yu Y; Zhao X; Chen M; Luo B; Wang J; Sun J
Thorac Cancer; 2019 Apr; 10(4):751-760. PubMed ID: 30734490
[TBL] [Abstract][Full Text] [Related]
20. Prognostic nomogram predicts overall survival in pulmonary large cell neuroendocrine carcinoma.
He Y; Liu H; Wang S; Chen Y
PLoS One; 2019; 14(9):e0223275. PubMed ID: 31560723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
